Co-Treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-Responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Pegvisomant (Primary) ; Lanreotide; Octreotide
- Indications Acromegaly
- Focus Therapeutic Use
- 25 Jan 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.